A PK/PD study on antihyperalgesia by an α2/3‐GABA <sub>A</sub> receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1‐GABA <sub>A</sub> receptors
Antihyperalgesic effects of TPA023B do not undergo tolerance development. Besides γ2-GABA<sub>A</sub>Rs, γ1-GABA<sub>A</sub>Rs appear to contribute to the antihyperalgesic effects of TPA023B. γ1-GABA<sub>A</sub>R selective PAMs may hence have a therapeutic potential in chronic pain conditions.
Authors
- Thomas Grampp
- Dietmar Benke (ORCID: https://orcid.org/0000-0003-1846-4711)
- Hanns Ulrich Zeilhofer (ORCID: https://orcid.org/0000-0001-6954-4629)
- M. Oana Popa (ORCID: https://orcid.org/0000-0002-2766-6801)
- Thomas Hathaway
- Marcus Hanley
- Daniel Ulrich
- Karen T Elvers (ORCID: https://orcid.org/0000-0001-5345-8662)
- Gui Jie Feng (ORCID: https://orcid.org/0000-0002-6145-8504)
- Elena Neumann
- John R. Atack
- Misa Oyama
- William T. Ralvenius
Institutions
- University of Zurich (CH)
- ETH Zurich (CH)
- University Hospital of Zurich (CH)
- University of Wales Institute Cardiff (SG)
- École Polytechnique Fédérale de Lausanne (CH)
- Cardiff University (GB)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1111/bph.70301
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Universität Zürich
- Medical Research Council